Revolution Medicines (RVMD) analyst forecast and price target
Analyst forecast
Consensus of 21 analyst ratings
Based on 15 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Needham | Maintained | Buy | $275.00 | Oct 15, 2026 |
| RBC Capital | Maintained | Outperform | $260.00 from $259.00 | Oct 14, 2026 |
| RBC Capital | Maintained | Outperform | $259.00 from $251.00 | Oct 8, 2026 |
| Truist Securities | Maintained | Buy | $240.00 from $239.00 | Oct 7, 2026 |
| Brookline Capital | Initiated Coverage | Buy | $318.00 | Sep 28, 2026 |
| Goldman Sachs | Maintained | Buy | $267.00 | Sep 24, 2026 |
| B of A Securities | Maintained | Buy | $265.00 from $225.00 | Sep 21, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $255.00 | Sep 10, 2026 |
| Stifel | Maintained | Buy | $230.00 from $215.00 | Sep 9, 2026 |
| Needham | Maintained | Buy | $275.00 from $240.00 | Aug 31, 2026 |
| Guggenheim | Maintained | Buy | $275.00 from $240.00 | Aug 28, 2026 |
| UBS | Maintained | Buy | $265.00 from $220.00 | Aug 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $280.00 from $195.00 | Aug 27, 2026 |
| Evercore ISI Group | Maintained | Outperform | $320.00 from $230.00 | Aug 27, 2026 |
| Truist Securities | Maintained | Buy | $239.00 from $231.00 | Aug 27, 2026 |
| Wedbush | Maintained | Outperform | $225.00 from $201.00 | Aug 27, 2026 |
| RBC Capital | Maintained | Outperform | $251.00 from $203.00 | Aug 27, 2026 |
| Oppenheimer | Maintained | Outperform | $260.00 from $230.00 | Aug 27, 2026 |
| Bernstein | Maintained | Market Perform | $179.00 from $151.00 | Aug 21, 2026 |
| Truist Securities | Maintained | Buy | $231.00 from $210.00 | Aug 11, 2026 |
Frequently asked questions
What is the price target for RVMD stock?
The average 12-month analyst price target for Revolution Medicines (RVMD) is $260.93, with a high estimate of $320.00 and a low of $179.00, across 15 analysts.
Is RVMD a buy, sell, or hold?
Analysts covering Revolution Medicines currently average a Buy rating: 20 buy, 1 hold and 0 sell, from 21 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for RVMD?
The average price target of $260.93 implies 34.84% upside from the last price of $193.52.
What is the latest analyst rating on RVMD?
On Oct 15, 2026, Needham maintained Revolution Medicines at Buy with a price target of $275.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.